Clinical Study

Chemoid Cg03-Eoc- Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy In Recurrent Platinum Resistant Ovarian Cancer

Posted Date: Dec 30, 2019

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Oncology, Ovarian Cancer
  • Type of Study: Drug

The purpose of this study is to study Overall Response rate, progression free survival, and duration of response in standard chemotherapy vs Stem cell directed chemotherapy in recurrent ovarian cancer.

Criteria:

To Be Eligible: Diagnosed With Recurrent Epithelial Ovarian, Peritoneal, Or Fallopian Tube Carcinoma, >18 Years Of Age, Life Expectency >6 Months, No Severe Medical Conditions Or Infections That Would Interfere With Study

Keywords:

Ovarian Cancer, Peritoneal Cancer, Oncology

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.